Analysts' Opinions on ISRG Stock

Intuitive Surgical stock is trading -8.33% below its average target price of $410.8 after dropping -1.5% during today's morning session. Analysts are giving the large-cap Medical Instruments & Supplies company an average rating of buy and target prices ranging from $322.5 to $460.0 per share.

The stock has a very low short interest at 0.9%, and a short ratio of 1.46. The company's insiders own 0.51% of its outstanding shares, which indicates a strong alignment between management and shareholder interests. Finally, we also note that a significant number of institutional investors are invested in the stock, with 88.5% of Intuitive Surgical's shares being owned by this investor type.

Institutions Invested in Intuitive Surgical

Date Reported Holder Percentage Shares Value
2023-09-30 Blackrock Inc. 9% 30,035,542 $11,310,484,270
2023-09-30 Vanguard Group Inc 8% 29,868,227 $11,247,478,460
2023-09-30 Price (T.Rowe) Associates Inc 5% 16,700,525 $6,288,916,821
2023-09-30 State Street Corporation 4% 14,644,433 $5,514,654,242
2023-09-30 FMR, LLC 2% 7,723,962 $2,908,612,426
2023-09-30 Capital World Investors 2% 7,558,658 $2,846,363,898
2023-09-30 Geode Capital Management, LLC 2% 6,773,068 $2,550,534,266
2023-09-30 Alliancebernstein L.P. 2% 6,766,225 $2,547,957,397
2023-12-31 Bank Of New York Mellon Corporation 2% 6,706,824 $2,525,588,762
2023-09-30 Morgan Stanley 2% 5,318,872 $2,002,927,667

Besides an analyst consensus of some upside potential, other market factors point to there being mixed market sentiment on Intuitive Surgical.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.